This HTML5 document contains 142 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00626/identifier/wikipedia/
n15http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00626/identifier/pharmgkb/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00626/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/mixture/
n13http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00626/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00626/identifier/drugbank/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00626/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00626/identifier/chebi/
n26http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00626
rdf:type
n3:Drug
n3:description
Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy. As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically. Bacitracin is synthesised via the so-called nonribosomal peptide synthetases (NRPSs), which means that ribosomes are not involved in its synthesis.
n3:dosage
n11:271B5A77-363D-11E5-9242-09173F13E4C5 n11:271B5A78-363D-11E5-9242-09173F13E4C5 n11:271B5A79-363D-11E5-9242-09173F13E4C5 n11:271B5A7A-363D-11E5-9242-09173F13E4C5 n11:271B5A76-363D-11E5-9242-09173F13E4C5 n11:271B5A83-363D-11E5-9242-09173F13E4C5 n11:271B5A84-363D-11E5-9242-09173F13E4C5 n11:271B5A7F-363D-11E5-9242-09173F13E4C5 n11:271B5A80-363D-11E5-9242-09173F13E4C5 n11:271B5A81-363D-11E5-9242-09173F13E4C5 n11:271B5A82-363D-11E5-9242-09173F13E4C5 n11:271B5A7B-363D-11E5-9242-09173F13E4C5 n11:271B5A7C-363D-11E5-9242-09173F13E4C5 n11:271B5A7D-363D-11E5-9242-09173F13E4C5 n11:271B5A7E-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Tay WM, Epperson JD, da Silva GF, Ming LJ: 1H NMR, mechanism, and mononuclear oxidative activity of the antibiotic metallopeptide bacitracin: the role of D-Glu-4, interaction with pyrophosphate moiety, DNA binding and cleavage, and bioactivity. J Am Chem Soc. 2010 Apr 28;132(16):5652-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20359222 # Karala AR, Ruddock LW: Bacitracin is not a specific inhibitor of protein disulfide isomerase. FEBS J. 2010 Jun;277(11):2454-62. Epub 2010 Apr 30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20477872
n3:group
approved
n3:indication
For the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. Also used in ointment form for topical treatment of a variety of localized skin and eye infections, as well as for the prevention of wound infections. Used against gram positive bacteria. Bacitracin is also used as an inhibitor of proteases and other enzymes. However, specific activity of bactracin's inhibition of protein disulfide isomerase has been called into question.
n3:manufacturer
n4:271B5A6F-363D-11E5-9242-09173F13E4C5 n4:271B5A69-363D-11E5-9242-09173F13E4C5 n4:271B5A6A-363D-11E5-9242-09173F13E4C5 n4:271B5A67-363D-11E5-9242-09173F13E4C5 n4:271B5A68-363D-11E5-9242-09173F13E4C5 n4:271B5A6D-363D-11E5-9242-09173F13E4C5 n4:271B5A6E-363D-11E5-9242-09173F13E4C5 n4:271B5A6B-363D-11E5-9242-09173F13E4C5 n4:271B5A6C-363D-11E5-9242-09173F13E4C5 n4:271B5A65-363D-11E5-9242-09173F13E4C5 n4:271B5A66-363D-11E5-9242-09173F13E4C5 n4:271B5A63-363D-11E5-9242-09173F13E4C5 n4:271B5A64-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00626 n16:DB00626
dcterms:title
Bacitracin
adms:identifier
n19:0009-0233-01 n20:PA448531 n21:28669 n22:C01667 n23:D00128 n24:Bacitracin n25:DB00626
n3:mechanismOfAction
Bacitracin intereferes with the dephosphorylation of the 55-carbon, biphosphate lipid transport molecule C55-isoprenyl pyrophosphate (undecaprenyl pyrophosphate), which carries the building blocks of the peptidoglycan bacterial cell wall outside the inner membrane for construction. Bacitracin binds divalent transition metal ions (Mn(II), Co(II), Ni(II), Cu(II), and Zn(II)) which binds and oxidatively cleave DNA.
n3:packager
n4:271B5A5B-363D-11E5-9242-09173F13E4C5 n4:271B5A58-363D-11E5-9242-09173F13E4C5 n4:271B5A59-363D-11E5-9242-09173F13E4C5 n4:271B5A61-363D-11E5-9242-09173F13E4C5 n4:271B5A62-363D-11E5-9242-09173F13E4C5 n4:271B5A5F-363D-11E5-9242-09173F13E4C5 n4:271B5A60-363D-11E5-9242-09173F13E4C5 n4:271B5A56-363D-11E5-9242-09173F13E4C5 n4:271B5A57-363D-11E5-9242-09173F13E4C5 n4:271B5A54-363D-11E5-9242-09173F13E4C5 n4:271B5A55-363D-11E5-9242-09173F13E4C5 n4:271B5A53-363D-11E5-9242-09173F13E4C5 n4:271B5A5E-363D-11E5-9242-09173F13E4C5 n4:271B5A5C-363D-11E5-9242-09173F13E4C5 n4:271B5A5D-363D-11E5-9242-09173F13E4C5 n4:271B5A5A-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The drug is excreted slowly by glomerular filtration.
n3:synonym
Bacitracin F, 1-(N-((2-(1-amino-2-methylbutyl)-4,5-dihydro-4-thiazolyl)carbonyl)-L-leucine)- Bacitracin a2a
n3:toxicity
Oral, mouse: LD<sub>50</sub> = >3750 mg/kg.
n14:hasAHFSCode
n15:08-12-28-08 n15:84-04-04
n3:mixture
n8:271B5A4B-363D-11E5-9242-09173F13E4C5 n8:271B5A4C-363D-11E5-9242-09173F13E4C5 n8:271B5A33-363D-11E5-9242-09173F13E4C5 n8:271B5A4F-363D-11E5-9242-09173F13E4C5 n8:271B5A50-363D-11E5-9242-09173F13E4C5 n8:271B5A4D-363D-11E5-9242-09173F13E4C5 n8:271B5A4E-363D-11E5-9242-09173F13E4C5 n8:271B5A51-363D-11E5-9242-09173F13E4C5 n8:271B5A52-363D-11E5-9242-09173F13E4C5 n8:271B5A36-363D-11E5-9242-09173F13E4C5 n8:271B5A37-363D-11E5-9242-09173F13E4C5 n8:271B5A34-363D-11E5-9242-09173F13E4C5 n8:271B5A35-363D-11E5-9242-09173F13E4C5 n8:271B5A3A-363D-11E5-9242-09173F13E4C5 n8:271B5A3B-363D-11E5-9242-09173F13E4C5 n8:271B5A38-363D-11E5-9242-09173F13E4C5 n8:271B5A39-363D-11E5-9242-09173F13E4C5 n8:271B5A45-363D-11E5-9242-09173F13E4C5 n8:271B5A46-363D-11E5-9242-09173F13E4C5 n8:271B5A43-363D-11E5-9242-09173F13E4C5 n8:271B5A44-363D-11E5-9242-09173F13E4C5 n8:271B5A49-363D-11E5-9242-09173F13E4C5 n8:271B5A4A-363D-11E5-9242-09173F13E4C5 n8:271B5A47-363D-11E5-9242-09173F13E4C5 n8:271B5A48-363D-11E5-9242-09173F13E4C5 n8:271B5A3D-363D-11E5-9242-09173F13E4C5 n8:271B5A3E-363D-11E5-9242-09173F13E4C5 n8:271B5A3C-363D-11E5-9242-09173F13E4C5 n8:271B5A41-363D-11E5-9242-09173F13E4C5 n8:271B5A42-363D-11E5-9242-09173F13E4C5 n8:271B5A3F-363D-11E5-9242-09173F13E4C5 n8:271B5A40-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Brigt Oystese, "Zinc bacitracin composition for use as a feed supplement and method for making the same." U.S. Patent US4096246, issued December, 1963.
foaf:page
n7:bacitracin-ointment.html n9:bacit.htm
n3:IUPAC-Name
n5:271B5A89-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5A8F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5A8E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5A8B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5A8C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5A8D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5A9F-363D-11E5-9242-09173F13E4C5 n5:271B5A87-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5A88-363D-11E5-9242-09173F13E4C5 n5:271B5A85-363D-11E5-9242-09173F13E4C5 n5:271B5AA1-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5A86-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n26:J01XX10 n26:R02AB04 n26:D06AX05
n3:H-Bond-Acceptor-Count
n5:271B5A95-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5A96-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5A90-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5A91-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5A93-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5A92-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5A94-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption of bacitracin following intramuscular injection is rapid and complete. Absorption from the gastrointestinal tract following oral administration is not appreciable. Absorption following topical application is negligible.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
1405-87-4
n3:containedIn
n17:271B5A71-363D-11E5-9242-09173F13E4C5 n17:271B5A72-363D-11E5-9242-09173F13E4C5 n17:271B5A70-363D-11E5-9242-09173F13E4C5 n17:271B5A75-363D-11E5-9242-09173F13E4C5 n17:271B5A73-363D-11E5-9242-09173F13E4C5 n17:271B5A74-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5A9B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5A9D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5A9E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B5AA0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5A9A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5A99-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5A9C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5A8A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B5A97-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5A98-363D-11E5-9242-09173F13E4C5